Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2026 (three months ended December 31, 2025) and Provides Conference Call Information
Northvale, New Jersey--(Newsfile Corp. - February 17, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced results for the third quarter of fiscal year 2026, the three months ended December 31, 2025 ("Third Quarter"). Consolidated revenues for the three-month period ending December 31, 2025, were $31.6 million, an increase of $17.2 million or approximately 120% as compared
Healthcare and Hospitals, Pharmaceuticals, Health
2026-02-17 4:19 PM EST | Elite Pharmaceuticals, Inc.
Functional Brands Inc. Introduces Kirkman's(R) Exciting New Restorative Sleep Bundle for Deep, Refreshing Sleep Without Grogginess
Lake Oswego, Oregon--(Newsfile Corp. - February 17, 2026) - Functional Brands Inc. (NASDAQ: MEHA), a leading innovator in wellness and performance products, is thrilled to announce the launch of the new Kirkman® Restorative Sleep Bundle, a carefully formulated combination designed to promote deep, restorative sleep and calm the nervous system-without the morning grogginess commonly associated with sleep aids. The bundle features Herbal Sleep Aid (melatonin-free), GABA 25
Household / Consumer / Cosmetics, Health
2026-02-17 8:00 AM EST | Functional Brands Inc.
Safe Supply Announces Sale of Two NIRLAB Drug Analysis Devices Supporting Indigenous-Led Community Safety Initiatives
Toronto, Ontario--(Newsfile Corp. - February 17, 2026) - Safe Supply Streaming Co Ltd. (CSE: SPLY) (OTCQB: SSPLF) (FSE: QM4) ("Safe Supply" or the "Company") today announced the sale of two NIRLAB SA ("NIRLAB") drug analysis devices to a First Nation community to support local safety, health, and emergency-response initiatives. The deployment of two additional NIRLAB devices expands access to rapid, field-deployable drug identification technology within Indi
2026-02-17 7:12 AM EST | Safe Supply Streaming Co Ltd.
Optimi Health Reports First MDMA-Assisted Treatments of 2026 are Underway Across an Expanded Network of Australian Clinics
Vancouver, British Columbia--(Newsfile Corp. - February 17, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Health Canada-licensed manufacturer of pharmaceutical psychedelic drug products, today reported that the first patients of 2026 have been treated using the Company's MDMA capsules at authorised clinics across Australia, operating under the Authorised Prescriber Scheme. The Company continues to supply its finished MDMA drug product d
Biotechnology, Pharmaceuticals, Health, Psychedelics
2026-02-17 7:00 AM EST | Optimi Health Corp.
QScreen AI Advances Quantum-Inspired Optimization with U.S. Patent Filing; Gains National Spotlight on CBC
Toronto, Ontario--(Newsfile Corp. - February 17, 2026) - QScreen AI Inc (CSE: QAI) (OTC Pink: PMEDF) (FSE: 3QP), an innovator fusing Quantum-AI technologies to transform health screening and employee wellness, today announced the filing of a provisional patent application with the United States Patent and Trademark Office (USPTO). Entitled "System, Method, and Robotic Platform for Quantum-Inspired Multi-Objective Optimization of Human-Governed Clinical Intake and Readiness Data Collection Und
2026-02-17 7:00 AM EST | QScreen AI Inc.
Adia Nutrition Announces Subsidiary Adia Med's Submission of Second Clinical Study for IRB Review Targeting Lower Back Pain with AdiaVita
Winter Park, Florida--(Newsfile Corp. - February 16, 2026) - Adia Nutrition Inc. (OTCQB: ADIA), a leader in regenerative medicine and innovative therapeutic solutions, today announced that its subsidiary, Adia Med of Winter Park, LLC, has submitted its second clinical study for Institutional Review Board (IRB) review. This pivotal study will evaluate the efficacy of AdiaVita, Adia Med's proprietary umbilical cord blood-derived stem cell and exosome product, in alleviating lower back pain thro
Healthcare and Hospitals, Health
2026-02-16 9:00 AM EST | Adia Nutrition Inc.
Optimi Health meldet Beginn der ersten MDMA-gestützten Behandlungen im Jahr 2026 in einem erweiterten Netzwerk australischer Kliniken
Vancouver, British Columbia--(Newsfile Corp. - Montag, 16. Februar 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" oder das "Unternehmen"), ein von Health Canada lizenzierter Hersteller pharmazeutischer psychedelischer Arzneimittelprodukte, gab heute bekannt, dass die ersten Patientinnen und Patienten des Jahres 2026 in autorisierten Kliniken in ganz Australien mit den MDMA-Kapseln des Unternehmens behandelt wurden. Die Behandlungen erfolgen im Rahmen des Authorise
Biotechnology, Pharmaceuticals, Health, Psychedelics
2026-02-16 1:00 AM EST | Optimi Health Corp.
Restart Life Sciences Executes Definitive Agreement to Acquire Holy Crap Foods
Vancouver, British Columbia--(Newsfile Corp. - February 13, 2026) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") is pleased to announce that, further to its news release dated December 22, 2025, it has entered into a share purchase agreement (the "Definitive Agreement") among Holy Crap Foods Inc. ("Holy Crap") and Happy Belly Coffee Inc. (the "Vendor"), a subsidiary of Happy Belly Food Group Inc. (CSE: HBFG) that owns all of the issue
Technology, Biotechnology, Health
2026-02-13 10:10 AM EST | Restart Life Sciences Corp.
Medexus Announces Fiscal Q3 2026 Results, Driven by Continued Strong Year-To-Date Product-Level Performance of GRAFAPEX (treosulfan) for Injection
Ontario and Chicago, Illinois--(Newsfile Corp. - February 11, 2026) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced its operating and financial results and provided a business update for the company's third fiscal quarter ended December 31, 2025 (the company's fiscal Q3 2026). All dollar amounts in this press release are in US dollars unless specified otherwise. Key update on GRAFAPEX Medexus has continued to see a positive market response to GR
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-02-11 5:30 PM EST | Medexus Pharmaceuticals Inc.
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2026 Financial Results on February 18, 2026
Northvale, New Jersey--(Newsfile Corp. - February 11, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced today that the third quarter financial results of the 2026 fiscal year will be released on Tuesday, February 17, 2026. Elite's management will host a live conference call on Wednesday, February 18th, at 11:30 AM EST to discuss the company's financial and operating
Healthcare and Hospitals, Pharmaceuticals, Health
2026-02-11 4:30 PM EST | Elite Pharmaceuticals, Inc.
Rapid Dose Therapeutics Begins Trading on the OTCQB in the United States Under Symbol RDTCF, Expanding Access for U.S. Healthcare and Biotechnology Investors
Burlington, Ontario--(Newsfile Corp. - February 11, 2026) - Rapid Dose Therapeutics Corp. (CSE: DOSE) (OTCQB: RDTCF) ("RDT" or the "Company"), a Canadian biotechnology company revolutionizing drug delivery through innovation, today announced that its common shares are now trading in the United States on the OTCQB Venture Market under the ticker symbol RDTCF. The OTCQB listing expands Rapid Dose Therapeutics' presence in the U.S. capital markets by increasing accessibili
2026-02-11 11:21 AM EST | Rapid Dose Therapeutics Corp.
Tersis Technologies Welcomes Daniel "Jack" Gaido, Jr. to Its Board of Directors
Brooksville, Florida--(Newsfile Corp. - February 11, 2026) - Tersis Technologies, Inc. (OTCID: TERS) a systems-focused energy and infrastructure company advancing regenerative solutions through practical integration, today announced the appointment of Daniel "Jack" Gaido, Jr. to its Board of Directors.
Agriculture, Energy, Alternative Energy, Health
2026-02-11 10:03 AM EST | Tersis Technologies Inc.
NurExone Biologic Advances Manufacturing and Regulatory Roadmap with Independent Batch Consistency Results for Exosome Production
Ontario and Haifa, Israel--(Newsfile Corp. - February 10, 2026) - NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) ("NurExone" or the "Company"), a biopharmaceutical company developing exosome-based regenerative therapies for central nervous system injuries, today announced results from an independent proteomic analysis conducted at the Technion - Israel Institute of Technology. which evaluated multiple production batches of NurExone's exosomes. The results
Biotechnology, Pharmaceuticals, Health
2026-02-10 4:03 PM EST | NurExone Biologic Inc.
Apollo Biowellness Executes Letter Of Intent with Medwell AI, Inc.
North Bergen, New Jersey--(Newsfile Corp. - February 10, 2026) - Apollo Biowellness, Inc. (OTCID: KOAN) (the "Company) is pleased to announce the signing of a Letter of Intent ("LOI") to create a vertically integrated health, wellness and longevity platform.
Household / Consumer / Cosmetics, Health
2026-02-10 9:30 AM EST | Apollo Biowellness, Inc.
Mobile-health Network Solutions Launches Otter.SG, an AI-Powered Clinic Operating System for Hybrid Care
Singapore, Singapore--(Newsfile Corp. - February 10, 2026) - Mobile-health Network Solutions (NASDAQ: MNDR) ("MNDR" or the "Company"), a leading AI HealthTech platform, today announced the global launch, effective immediately, of Otter.SG, an AI-powered SaaS clinic management platform that unifies clinical, operational, and financial workflows in a single system. Unlike traditional healthcare practice management systems that typically focus on scheduling or billing
2026-02-10 8:41 AM EST | Mobile-health Network Solutions
Aleen Inc. Insights: What Are AI Agents and How They Fit Into Digital Wellness
Toronto, Ontario--(Newsfile Corp. - February 10, 2026) - Aleen Inc. (CSE: ALEN.U), a digital wellness company, shares an educational overview of AI agents — what they are, how they function, and why they are becoming an important area of exploration within digital products focused on user interaction and insight delivery. AI agents are software-based systems designed to perform defined tasks autonomously or semi-autonomously within digital environments. Unlike static
2026-02-10 8:00 AM EST | Aleen Inc.
Beckett's Launches in BevMo! Stores Across California
Ontario and Los Angeles, California--(Newsfile Corp. - February 10, 2026) - Beckett's Inc. (CSE: BKTS), a fast-growing non-alcoholic beverage brand, announced today that its ready-to-drink non-alcoholic cocktails are rolling out at BevMo! locations across California. The initial launch will feature Beckett's Tonics® Non-Alcoholic Gin & Tonic and upon completion of its next production run, be followed by best seller Beckett's Tonics® Non-Alcoholic Moscow Mule. The
Food / Beverages, Cannabis, Health
2026-02-10 7:30 AM EST | Becketts Inc.
Neural Portfolio Company Hanf.com Reports Strong Fiscal 2025 Results with 58% Revenue Growth and Positive Normalized Operating Income
Toronto, Ontario--(Newsfile Corp. - February 10, 2026) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company"), an ethnobotanical drug discovery company focused on developing therapeutic solutions for mental health conditions related to substance use disorders, together with its portfolio company CWE European Holdings Inc. ("CWE"), operating as Hanf.com, one of Germany's leading CBD retailers, is pleased to report preliminary unaudited financ
Biotechnology, Pharmaceuticals, Health, Psychedelics
2026-02-10 7:30 AM EST | Neural Therapeutics Inc.
Cardiol Therapeutics' ARCHER Phase II Study Results Published in ESC Heart Failure
Toronto, Ontario--(Newsfile Corp. - February 10, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease, today announced the publication of results from its Phase II ARCHER study in ESC Heart Failure, a journal of the European Society of Cardiology. The peer-reviewed article reports resu
Biotechnology, Cannabis, Health, Cannabis Manufacturer
2026-02-10 7:27 AM EST | Cardiol Therapeutics Inc.
Phio Announces Safety Monitoring Committee's (SMC) Positive Wrap-up on Lead Clinical Candidate PH-762 in Skin Cancer Trial
King of Prussia, Pennsylvania--(Newsfile Corp. - February 10, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary IN
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-02-10 7:00 AM EST | Phio Pharmaceuticals Corp.